Brain Sciences | Free Full-Text | Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series
Form 10-K
Soliris® (eculizumab)
Alexion Pharmaceuticals: Patent Resolution Is Too Little Too Late (NASDAQ:ALXN) | Seeking Alpha
SOLIRIS® (eculizumab) HCP | MOA
Soliris® (eculizumab) 300 mg (10 mg/mL) Intravenous (IV) Infusion.
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2) (NASDAQ:ALXN) | Seeking Alpha
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1) (NASDAQ:ALXN) | Seeking Alpha
SEC Filing | Alexion Pharmaceuticals, Inc.
July August 2019 Clinical Rx Forum Newsletter.pub
Alexion: download vector logo and get Alexion Pharmaceuticals brand information and colors.
Preventing meningococcal disease in patients receiving Soliris
SOLIRIS® (ECULIZUMAB)
Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab
ALEXION PHARMACEUTICALS, INC.
Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study
July August 2019 Clinical Rx Forum Newsletter.pub
CONCLUSIONS ACKNOWLEDGMENTS DISCLOSURES REFERENCES James F. Howard, Jr,1 Richard J. Nowak,2 Gil I. Wolfe,3 Michael G. Benatar,4
g993172.jpg
Reference ID: 4227466
SOLIRIS® (eculizumab) HCP | MOA
SPECIALTY GUIDELINE MANAGEMENT
Initial Criteria:
SEC Filing | Alexion Pharmaceuticals, Inc.
